First Emergence of acrAB and oqxAB Mediated Tigecycline Resistance in Clinical Isolates of *Klebsiella pneumoniae* Pre-Dating the Use of Tigecycline in a Chinese Hospital

Xue Zhong1,2, Hongtao Xu3, Dongke Chen3, Haijian Zhou4,5, Xin Hu2, Gang Cheng1*

1. Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, PR China, 2. Department of Pharmacy, Beijing Hospital, Beijing, PR China, 3. Department of Clinical Laboratory, Beijing Hospital, Beijing, PR China, 4. State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, PR China, 5. Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, Hangzhou, PR China

*chenggang63@hotmail.com

Abstract

Tigecycline is one of the few therapeutic options for treating infections caused by some multi-drug resistant pathogens, such as *Klebsiella pneumoniae*. However, tigecycline-resistant *K. pneumoniae* has been discovered recently in China. From 2009 to 2013, nine tigecycline-resistant *K. pneumoniae* isolates were identified in our hospital. Six of nine strains were identified before using tigecycline. To investigate the efflux-mediated resistance mechanisms of *K. pneumoniae*, the expression of efflux pump genes (acrA, acrB, tolC, oqxA and oqxB) and pump regulators (acrR, marA, soxS, rarA, rob and ramA) were examined by real-time RT-PCR. Molecular typing of the tigecycline resistant strains was performed. ST11 was the predominant clone of *K. pneumoniae* strains, while ST1414 and ST1415 were novel STs. Efflux pump inhibitor (EPI)-carbonyl cyanide chlorophenylhydrazone (CCCP) was able to reverse the resistance patterns of 5 resistant *K. pneumoniae* strains. In comparison with strain A111, a tigecycline-susceptible strain (negative control), we found that the expression levels of efflux pump genes and pump regulators were higher in a majority of resistant strains. Higher expression levels of regulators rarA (2.41-fold, 9.55-fold, 28.44-fold and 18.31-fold, respectively) and pump gene oqxB (3.87-fold, 31.96-fold, 50.61-fold and 29.45-fold, respectively) were observed in four tigecycline resistant strains (A363, A361, A368, A373, respectively). Increased expression of acrB was associated with ramA and marA.
expression. To our knowledge, studies on tigecycline resistance mechanism in \textit{K. pneumoniae} are limited especially in China. In our study, we found that both efflux pump AcrAB-TolC and OqxAB contributed to tigecycline resistance in \textit{K. pneumoniae} isolates.

**Introduction**

A derivative of minocycline, tigecycline, is a new class of glycylicyclines. It exhibits a broad-spectrum of activity against most of Gram-positive, Gram-negative pathogens, anaerobes, and ‘atypical’ bacteria \cite{1}. However, tigecycline-resistance has emerged recently in different pathogens such as \textit{Acinetobacter baumannii}, \textit{Klebsiella pneumoniae} and \textit{Enterobacteriaceae}, especially in multidrug-resistant (MDR) strains. Over the period 2007 to 2013, there have been 13 reports of tigecycline-resistant strains from USA, UK, France, Saudi Arabia, Greece, Spain, Germany and Taiwan and, among them, four were \textit{K. pneumoniae}, seven were \textit{A. baumannii}, one was \textit{Enterobacter hormaechei}, one was \textit{Enterococcus faecalis} and one was \textit{Bacteroides fragilis} \cite{2}. Also, most of them were changed from tigecycline-susceptible to tigecycline-resistant during treatment. The highest minimum inhibitory concentration (MIC) of tigecycline was 24 \textmu g/mL \cite{3}. Recently, emergence of non-susceptibility to tigecycline has also been reported in \textit{A. baumannii} and \textit{K. pneumoniae} in Mainland China \cite{4,5}. Here, we present nine cases of tigecycline-resistant \textit{K. pneumoniae} in Mainland China. Tigecycline was approved by the US Food and Drug Administration (FDA) in 2005 and was launched in Mainland China in 2011. However, we have discovered six strains resistant to tigecycline isolated before 2011 which shows that there existed tigecycline-resistant strains before using tigecycline. This phenomenon was in accordance with tigecycline-resistant report of Rosenblum et al. which pointed out that tigecycline resistance predates its introduction \cite{6}. We hypothesized that mechanisms of cross-resistance or other as-yet-undefined regulatory elements could be active in such strains. Currently, Veleba M et al. have shown that the factors for decreased sensitivity to tigecycline in \textit{K. pneumoniae} may be contribute to overexpression of the AcrAB RND-type and newly described OqxAB efflux pumps \cite{7}. In addition, the pumps were regulated by \textit{ramA}, \textit{marA}, \textit{soxS}, \textit{rarA} or \textit{rob} of transcriptional activators \cite{6,8–10}. The main purpose of this study was to investigate whether similar mechanisms existed in the resistant strains isolated from Mainland China or whether there are other reasons for this tigecycline resistance.
Materials and Methods

Bacterial strains
Two hundred and fifty-four carbapenem-resistant Enterobacteriaceae isolates were isolated from clinical samples of Beijing Hospital between 2009 and 2013. (belong to sample secondary use, free of informed consent and ethic). Identification of the strains was performed by using the VITEK-2 and susceptibility testing was carried out by Kirby-bauer, broth microdilution and E-test methods then ten K. pneumoniae isolates were selected to study the efflux mechanism. These consisted of nine K. pneumoniae isolates resistant to tigcyccline and one K. pneumoniae isolate, A111, susceptible to tigcyccline used as a negative control. Escherichia coli ATCC 25922 and K. pneumoniae ATCC 11296 were used as reference strains. The strains used in this study are shown in Table 1.

Tigcyccline susceptibility testing
Tigcyccline susceptibility testing was carried out using the following three different methods: Firstly, the Kirby-bauer method was used as a tigcyccline susceptibility test. Then, the minimum inhibitory concentrations (MICs) of tigcyccline were determined by standard broth microdilution tests and the E-test (BioMerieux), according to the Clinical and Laboratory Standards Institute (CLSI) recommendation and manufacturers’ instructions. The MICs for the strains were interpreted in accordance with FDA guidelines for tigcyccline, MIC ≤ 2 μg/mL and ≥ 8 μg/mL were classified as susceptible and resistant respectively. E. coli ATCC 25922 was used as the quality control strain.

Molecular typing by MLST
In order to check the clonality of the selected isolates, the ten isolates were typed by Multilocus sequence typing (MLST). MLST with seven housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) was performed in accordance with the protocol described on the K. pneumoniae MLST database. Alleles and sequence types (STs) of strains were assigned by using tools on the K. pneumoniae MLST database. BioNumerics version 5.10 software (Applied Maths, Kortrijk, Belgium) was used to create the minimum spanning tree [11] and in this, the founder ST was defined as the ST with the greatest number of single-locus variants. Types were represented by circles and the size of a circle indicated the number of strains with this particular type.

Efflux mechanism
The efflux pump inhibitor (EPI) carbonyl cyanide-chlorophenylhydrazone (CCCP; Sigma) was used to investigate the activity of the efflux pump in the tigcyccline-resistant and tigcyccline-susceptible K. pneumoniae isolates. The MICs of tigcyccline were determined by the broth microdilution method in the presence and absence of CCCP (fixed concentration of 16 μg/mL). If the MIC values
decreased 4-fold or greater in the presence of EPIs, this was defined as a significant inhibition effect [12].

**Real-time fluorescence quantitative PCR (RT-FQ-PCR)**

The expression levels of the \textit{acrR}, \textit{marA}, \textit{soxS}, \textit{rarA}, \textit{rob}, and \textit{ramA} regulator genes and the efflux components \textit{acrA}, \textit{acrB}, \textit{tolC}, \textit{oqxA} and \textit{oqxB} were assessed using RT-FQ-PCR. Oligonucleotide primers and probes used for RT-FQ-PCR (Table 2) were designed with Primer Express Software version 2.0 (Applied Biosystems) and purchased from Life Technologies (AB & Invitrogen). RNA was extracted using an EASYspin RNeasy Kit (Gene-Foci) then, for cDNA synthesis, a cDNA Synthesis Kit (Invitrogen) was used, according to the manufacturer’s instructions. The cDNAs were quantified by real-time PCR amplification with specific primers (Table 2) using a Taqman One-Step RT-PCR master mix reagents kit (Life Tech, USA) on a Life Tech 7500 Fast Real-Time PCR System (Applied Biosystems) with an initial incubation at 95˚C for 2 min, followed by 40 cycles of 10 s at 95˚C, 30 s at 60˚C, and 10 s at 72˚C. Each sample was processed in triplicate. In all cases, a housekeeping gene (\textit{rpoB}) was used to normalize the expression of the target genes for each isolate. The critical threshold cycle (C\textsubscript{T}) numbers were determined by the detection system software. The amount of target is given as \(2^{-\Delta C_T}\). Expression analysis was carried out to measure the relative expression of the mRNA compared with that of \textit{K. pneumoniae} A111.

**Results**

**Tigecycline susceptibility**

254 carbapenem-resistant \textit{Enterobacteriaceae} isolates included \textit{K. pneumoniae} (192 isolates), \textit{Escherichia coli} (41 isolates), \textit{Enterobacter cloacae} (12 isolates) and \textit{Enterobacter aerogenes} (9 isolates). Nine tigecycline-resistant \textit{K. pneumoniae}
isolates were obtained, a tigecycline nonsusceptibility rate of 4.69% (9/192) for carbapenem-resistant *K. pneumoniae*, One *Enterobacter cloacae* and one *Enterobacter aerogenes* besides *K. pneumoniae* also showed resistance to tigecycline but not the aim of this study. Of all the clinical carbapenem-resistant *K. pneumoniae* isolates, the tigecycline MIC ranged from 0.5–16 μg/ml with an MIC₅₀ of 4 μg/ml and an MIC₉₀ of 16 μg/ml. Nine *K. pneumoniae* clinical isolates were collected that required a tigecycline MIC over 8 μg/ml (Table 3). The highest MIC value of tigecycline was 16 μg/ml (A361, A363, A368, A373). In addition, an ordinary clinical strain A111 which was an ST11 type and susceptible to tigecycline was designated a negative control. So, nine resistant strains and one susceptible strain were included in this study. The susceptibility profiles of the ten strains are presented in Table 3.

**Molecular typing of the strains**

MLST analysis of nine isolates showed four different sequence types (STs). ST11 was the predominant ST, accounting for 6 (70%) of the isolates. Other three isolates belonged to ST378, ST1414 and ST1415, with 5, 4 and 5 loci different from ST11, respectively. ST1414 and ST1415 were novel STs identified for the first time in this study.

**Efflux pump activity**

The effect of the EPIs on tigecycline MICs is shown in Table 4. One strain (A103) showed an 8-fold decrease, four strains (A363R, A361, A368, A373) showed a 4-fold decrease, four strains (A352, A840, A916, A941) showed a 2-fold decrease in the tigecycline MIC in the presence of CCCP (16 μg/ml). There was no reduction in MIC observed in strain A111 under the same conditions.

---

**Table 2. Primers and fluorescent probes used for PCR.**

| Gene | Forward primer | Reverse primer | Fluorescent probe |
|------|----------------|----------------|------------------|
| ramA | TGCATCAACCGCTGCGTAT | GCGAATGAACGCCGACACTTGAG | TCGAAATGGGATCTGCCAAGCGGT |
| marA | GGAGATTGCGCAGAAAGTCGCA | GGATTGCGCAGGACTTCCTGCGA | CCAATCTGATCAGCTGGCAGG |
| soxS | GTGGACCTGACGCGGATGTG | CTGAGATGCTGATGCGGATGTC | CTATACGCGGACGGCGCCTG |
| rarA | CGATTGCGCTGCGAAGACGATGC | CCAGACGGACGAGATGACAGATG | CGTGCGGACTTTACGCGGTC |
| robA | TATTCATACCCACCCGCCTGAC | GTGCCGCTGACGCTGAGGATGC | CCTGCGGAATGCGGTCAGTC |
| acrA | GCCTATCATTGCGGGAAG | TTTAGCGGTCTGACAGTGGCT | TGAAGTATCCCGCACCGGTTC |
| acrB | GGAAGCGATCATCCTGGTGTT | ACCCGGAGGCTGCTAACA | TTCCTGGAATTTACCCGCGC |
| tolC | TACCAGCGAGGAGGTCATCA | GCGTTGCGGATCGACATGTGT | CGCGGAGTATCCGCTCGTG |
| oqxA | ATCAGGCGCGAAGTTCAGGAT | GCGACGTACCTGGTTTACCA | CAGCGGGAAGCAGATGG |
| oqxB | CGCAGCTTAACCTCGACTTCA | ACGAGCTTCGCGAGAACC | CCTATGCGGAGCGCAGG |
| acrR | CCTGCGGCGGTATTGAGGCTTAT | GGTAGCGTACCGGATACACG | TCAGTCGAGGCAGATGGTC |
| rpoB | GTGATTCCAGACCTGCGAATC | CCGGCGTATGACGAACACG | CGTCTGCGAAGCGGCGC |

Footnotes. TaqMan probe labeled with an FAM dye at the 5′ end and a minor groove binder (MGB) and nonfluorescent quencher (NFQ) at the 3′ end.

doi:10.1371/journal.pone.0115185.t002
Analysis of target pump genes and regulator expression

In our study, nine tigecycline-resistant strains were demonstrated to carry efflux pump genes and pump regulators. The relative x-fold increases in the pump genes and pump regulator levels were quantified after comparisons with *K. pneumoniae* A111 (Fig. 1 a-k). Compared with isolate A111, a higher expression level of regulator *rarA* (2.41-fold, 9.55-fold, 28.44-fold, and 18.31-fold, respectively) and pump gene *oqxB* (3.87-fold, 31.96-fold, 50.61-fold, 29.45-fold, respectively) was observed in four tigecycline-resistant strains (A363, A361, A368, A373, respectively). These data suggested that there was a correlation between the

### Table 3. Susceptibility profiles of nine tigecycline-resistant and one tigecycline-susceptible strain.

| Numbers of stains | KB(cm) | BMD(µg/mL) | E-test(µg/mL) |
|-------------------|--------|------------|---------------|
| ATCC 25922        | 25     | 0.125      | 0.125         |
| A103              | 6      | 8          | 16            |
| A352              | 12     | 8          | 8             |
| A840              | 14     | 8          | 6             |
| A916              | 13     | 8          | 6             |
| A941              | 14     | 8          | 8             |
| A363              | 9      | 16         | 16            |
| A361              | 10     | 16         | 16            |
| A368              | 9      | 16         | 16            |
| A373              | 10     | 16         | 16            |
| A111              | 19     | 2          | 2             |

Footnote. KB, Kirby-bauer; BMD, broth microdilution; MIC, minimum inhibitory concentration(test by BMD and E-test method) ; ATCC 25922 quality control strain KB value range from 20–27 cm, MIC range from 0.03–0.25 µg/mL.

doi:10.1371/journal.pone.0115185.t003

### Table 4. The MIC of tigecycline (TGC) in the multidrug resistant strains, with or without an efflux pump inhibitor, Carbonyl hydrogenated chlorophenyl hydrazone (CCCP).

| Numbers of stains | MIC(µg·mL⁻¹)     |
|-------------------|-----------------|
|                   | TGC | TGC. CCCP |
| ATCC 25922        | 0.125 | 0.125     |
| A103              | 8    | 1         |
| A352              | 8    | 4         |
| A840              | 8    | 4         |
| A916              | 8    | 4         |
| A941              | 8    | 4         |
| A363              | 16   | 4         |
| A361              | 16   | 4         |
| A368              | 16   | 4         |
| A373              | 16   | 4         |
| A111              | 2    | 2         |

Footnote. MIC, minimum inhibitory concentration; TGC, tigecycline; CCCP, carbonyl cyanide chlorophenylhydrazone. ATCC 25922 was used as negative quality control strain.

doi:10.1371/journal.pone.0115185.t004
increased expression of $oqxB$ and $rarA$. In addition, except for $oqxB$, the amount of $acrB$ transcript of the resistant strains was higher in comparison with strain A111. The expression of $acrB$ had an increased tendency with $ramA$ and $marA$ expression. Interestingly, the transcriptional levels of the $soxS$ gene, $acrR$ gene, and
rob gene, appeared to be linked to acrB expression, but the role of the three genes was not significant (data shown in Fig. 1).

**Discussion**

Tigecycline has been developed and has attracted much attention as the agent of last resort to treat clinical infections caused by multidrug-resistant *K. pneumoniae*. In 2011, tigecycline was first launched in Mainland China. However, we discovered six strains which were resistant to tigecycline before 2011, but it cannot be attributed to the use of tigecycline. We hypothesized that this resistance could be indirectly attributed to the use of other antibiotics which were also transported by the same efflux pump because tigecycline is a substrate of chromosomally encoded resistance-nodulation-division efflux pumps. A possible assumption was that these efflux systems were widely existing among *K. pneumoniae*. When strains exposed to some antibiotics which were substrates of efflux pumps, this might lead to overexpression of these efflux pumps. In addition to our report, other recent reports have described cross-resistance to tigecycline. Hornsey et al. and Deng et al. reported the emergence of resistance to tigecycline associated with other antibiotics rather than tigecycline [4, 13]. In addition, another study concluded that the use of carbapenems might induce resistance not only to carbapenems but also to many other antibiotics, including tigecycline [14]. These reports confirmed our assumption that our isolated tigecycline-resistant strains were likely related to overexpression of the efflux pump which caused cross-resistance.

It has been reported that antibiotic-resistance appeared to be mediated in part by active efflux systems [15, 16]. Recently some studies have demonstrated that efflux pump inhibitors (EPIs) are able to reverse resistance patterns by blocking bacterial pumps and preventing discharge of certain antibiotics [16]. In order to detect if there is an overexpression efflux in resistant *K. pneumoniae* strains, we used efflux pump inhibitors (EPIs) CCCP to assess the activity of the efflux pumps. In our study, CCCP restored the susceptibility in five strains (A103, A361, A363, A368, A373), indirectly proving that efflux pump overexpression contributed to tigecycline resistance. However, no significant reduction in tigecycline MICs was observed in the other four strains (A352, A840, A916, A941), indicating that CCCP was not effective. One possible explanation is that EPIs have different specificities towards various efflux pumps and interfere with them in a different manner. It may be that other EPIs, such as PABN, NMP, reserpine or verapamil, could restore the susceptibility of these strains. Also, the results (isolates A352, A840, A916, A941) of efflux pump activity (using CCCP) as well as the expression levels of target pump genes and its regulators suggested that it might have other mechanisms other than the overexpression of efflux pumps mediating tigecycline resistance.

It has been reported that resistance to tigecycline appears to be mediated in part by the active efflux systems AcrAB-TolC [8, 17]. Also, the AcrAB-TolC pump is
activated by several transcriptional regulators such as \textit{ramA}, \textit{marA}, \textit{soxS}, \textit{rob} or \textit{acrR}. These pump regulators play a role in promoting tigecycline resistance due to up-regulation of the efflux pump AcrAB-TolC \cite{9, 10, 18}. Our present study showed that the increased MIC for \textit{K. pneumoniae} strains correlated with the overexpression of \textit{ramA} or \textit{marA}, demonstrating that \textit{ramA} was not always needed to confer tigecycline-resistance, and \textit{marA} was also a global activator of the \textit{acrB} transporter (Fig. 1). A similar hypothesis was proposed recently, some studies have suggested that other pathways to tigecycline resistance must exist in \textit{K. pneumoniae} \cite{6, 7}. One of these studies demonstrated that a newly described OqxAB efflux pump could contribute to tigecycline resistance in \textit{K. pneumoniae} although the chromosomally encoded \textit{rarA} regulator lies downstream of the efflux pump OqxAB \cite{7}. In our study, the strains A363, A361, A373, and A368 had MIC values of 16 \(\mu\)g/ml, and quantitative real-time PCR analyses showed that \textit{rarA} overexpression was observed in conjunction with an elevated expression of the multidrug efflux pump OqxAB, confirming that \textit{raA} might be involved in the regulation of OqxAB production. The results presented here further support a previous report that \textit{rarA} is one of the regulator pathways that controls the expression of \textit{oqxB} in \textit{K. pneumoniae} \cite{19}. However, for the strains A840 and A916, although the expression level of \textit{rarA} was higher, this did not lead to overexpression of \textit{oqxB}; on the contrary, for the strains A941 and A103, the amount of the \textit{oqxB} transcript was higher, but the expression level of \textit{rarA} was not increased in comparison with the susceptible strain A111. This data indicates that some regulators other than \textit{rarA} may be able to contribute to \textit{oqxB} expression. In addition to our report, one recent report has described the same results. In that study, no differences in the sequences 5’ of \textit{oqxA} were found between two strains, which differed 20-fold in levels of \textit{oqxB} transcripts. Thus, they hypothesized the increased expression of \textit{oqxB} in the two strains appears not to be due to mutation in a putative promoter, but might relate to differences in other as-yet-undefined regulatory elements in these strains.\cite{20} We hypothesized that this was the reason why the MICs of four strains (A840, A916, A941, A103) were lower than those of the other strains (A363, A361, A368, A373). Efflux pumps AcrAB-TolC play an important role in strains with MICs of 8 \(\mu\)g/ml (A840, A916, A941, A103). For the strains with an MIC of 16 \(\mu\)g/ml (A363, A361, A368, A373), the AcrAB-TolC and OqxAB efflux pumps both contributed to the tigecycline-resistance. From our findings, it was clear that \textit{rarA} as well as those of the pump gene \textit{oqxB} were more important in the case of our selected tigecycline resistant \textit{K. pneumoniae} strains. This result was especially important with regard to the previous observations showing that a high-level of tigecycline resistance was exhibited due to alternative pathways in \textit{K. pneumoniae} \cite{7}. Irrespective of the nature of the pump acting in these strains, we have clearly demonstrated that the efflux pump plays a key role in the tigecycline-resistance in \textit{K. pneumoniae}. However, the mechanisms responsible for the high expression level of \textit{oqxB} leading to tigecycline-resistance remain unknown and need further study.

MLST was performed for molecular typing in the present study. ST11 is the epidemic clone of \textit{K. pneumoniae} carbapenemase 2-producing \textit{K. pneumoniae} in
China, and it had only one of the single-locus variants (SLVs) of ST258 which is the dominant clone in Eastern countries [21]. Other three STs had five to six loci different from ST11.

Conclusion

In conclusion, our study report mechanism of tigecycline-resistant _K. pneumoniae_ in Mainland China. The results of molecular typing suggest that the predominant clone of _K. pneumoniae_ strains was ST11. In addition, we identified two novel STs, namely ST1414 and ST1415. Efflux-mediated mechanisms, including high expression of AcrAB-ToIC and OqxAB efflux pumps appears to play a key role in tigecycline resistance while the pump regulators, _acrR, marA, soxS, rarA, rob_ and _ramA_, all make their individual contributions to the overexpression of AcrAB-ToIC and OqxAB efflux pumps. In addition, _rarA_ as well as the pump gene _oqxB_ are more important in our selected high level tigecycline-resistant _K. pneumoniae_ strains. Efflux pump inhibitors (EPIs)-CCCP was able to reverse resistance patterns in the majority of _K. pneumoniae_ strains. Although tigecycline is a promising antibiotic for the treatment of infections caused by multidrug-resistant _K. pneumoniae_, the development of tigecycline resistance is an issue of great concern.

Acknowledgments

We thank the team of the curators of the Institute Pasteur MLST system (Paris, France) for importing novel alleles, profiles and or isolates at [http://www.pasteur.fr/mlst](http://www.pasteur.fr/mlst).

Author Contributions

Conceived and designed the experiments: XZ GC XH. Performed the experiments: XZ HZ DC. Analyzed the data: XZ HX HZ. Contributed reagents/materials/analysis tools: DC XH. Wrote the paper: XZ GC HX.

References

1. Stein GE, Babinchak T (2013) Tigecycline: an update. Diagn Microbiol Infect Dis 75: 331–336.
2. Sun Y, Cai Y, Liu X, Bai N, Liang B, et al. (2013) The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 41: 110–116.
3. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM (2007) Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27: 1198–1201.
4. Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK, et al. (2014) Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother 58: 297–303.
5. Sheng ZK, Hu F, Wang W, Guo Q, Chen Z, et al. (2014) Mechanisms of Tigecycline Resistance among Klebsiella pneumoniae Clinical Isolates. Antimicrob Agents Chemother 58: 6982–6985.
6. Rosenblum R, Khan E, Gonzalez G, Hasan R, Schneiders T (2011) Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae. Int J Antimicrob Agents 38: 39–45.

7. Veleba M, Schneiders T (2012) Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae. Antimicrob Agents Chemother 56: 4466–4467.

8. Ruzin A, Visalli MA, Keeney D, Bradford PA (2005) Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49: 1017–1022.

9. Bratu S, Landman D, George A, Salvanji J, Quale J (2009) Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J Antimicrob Chemother 64: 278–283.

10. Perez A, Poza M, Aranda J, Latasa C, Medrano FJ, et al. (2012) Effect of transcriptional activators SoxS, RobA, and RamA on expression of multidrug efflux pump AcrAB-ToIC in Enterobacter cloacae. Antimicrob Agents Chemother 56: 6256–6266.

11. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186: 1518–1530.

12. Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK, et al. (2013) Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother.

13. Hornsey M, Ellington MJ, Doumith M, Scott G, Livermore DM, et al. (2010) Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int J Antimicrob Agents 35: 478–481.

14. Kuo HY, Chang KC, Kuo JW, Yueh HW, Liou ML (2012) Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii. Int J Antimicrob Agents 39: 33–38.

15. Pages JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, et al. (2009) Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One 4: e4817.

16. Hasdemir UO, Chevalier J, Nordmann P, Pages JM (2004) Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 42: 2701–2706.

17. Ruzin A, Immermann FW, Bradford PA (2008) Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 52: 3430–3432.

18. Roy S, Datta S, Viswanathan R, Singh AK, Basu S (2013) Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility. J Antimicrob Chemother 68: 1036–1042.

19. Veleba M, Higgins PG, Gonzalez G, Seifert H, Schneiders T (2012) Characterization of RarA, a novel AraC family multidrug resistance regulator in Klebsiella pneumoniae. Antimicrob Agents Chemother 56: 4450–4458.

20. Kim HB, Wang M, Park CH, Kim EC, Jacoby GA, et al. (2009) opxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother 53: 3582–3584.

21. Qi Y, Wei Z, Ji S, Du X, Shen P, et al. (2011) ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J Antimicrob Chemother 66: 307–312.